A Patient-Derived Organoid-Based Study Identified an ASO Targeting SNORD14E for Endometrial Cancer through Reducing Aberrant FOXM1 Expression and β-Catenin Nuclear Accumulation

The Cancer Genome Atlas database was used to determine SNORD14E expression. The effects of SNORD14E were investigated using CCK8, Transwell, wound-healing assays, and a xenograft model experiment; apoptosis was measured by flow cytometry.